Resistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mazandaran University of Medical Sciences and Health Services
2013-02-01
|
| Series: | Research in Molecular Medicine |
| Subjects: | |
| Online Access: | http://rmm.mazums.ac.ir/browse.php?a_code=A-10-589-1&slc_lang=en&sid=1 |